IRLAB enters collaboration agreement with Danish biotech company Biomia ApS applying the Integrative Screening Process (ISP)

Gothenburg, Sweden, January 19, 2026 — IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that it has entered into a collaboration with the Danish biotech company Biomia to evaluate Biomia’s drug candidates applying IRLAB’s discovery platform, the Integrative Screening Process (ISP).

IRLAB Receives Approval for a Phase Ib Study with IRL757 in Parkinson’s Disease

The European Patent Office intends to grant a new patent for IRLAB’s mesdopetam.